DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Akineton (Biperiden Hydrochloride) - Summary

 
 



AKINETON SUMMARY

AKINETON® Tablets
(biperiden hydrochloride)

Each AKINETON tablet for oral administration contains 2 mg biperiden hydrochloride. Other ingredients may include corn syrup, lactose, magnesium stearate, potato starch and talc. AKINETON is an anticholinergic agent. Biperiden is α-5-Norbornen-2-yl-α-phenyl-1-piperidinepropanol. It is a white, crystalline, odorless powder, slightly soluble in water and alcohol. It is stable in air at normal temperatures.

AKINETON (biperiden) is indicated for the following:

  • As an adjunct in the therapy of all forms of parkinsonism (idiopathic, postencephalitic, arteriosclerotic)
  • Control of extrapyramidal disorders secondary to neuroleptic drug therapy (e.g., phenothiazines)

See all Akineton indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Akineton (Biperiden)

Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: a randomized, double-blind, crossover study. [2010.06]
BACKGROUND: Clozapine-induced sialorrhea (CIS) is a subjective distressing adverse effect and occurs in 31%-57% of schizophrenic patients receiving clozapine therapy. Current pharmacotherapy on CIS has focused on anticholinergic agents, even though they may impair cognitive function. Previous case reports have suggested the benefit of glycopyrrolate or biperiden in treating this condition, but no randomized controlled trial has provided evidence. The objective of our study was to evaluate the efficacy and impact on cognition of glycopyrrolate and biperiden treatments for schizophrenic patients suffering from CIS... CONCLUSION: We provide evidence, for the first time, of the efficacy of glycopyrrolate and biperiden in the treatment of CIS. Furthermore, glycopyrrolate displays less impact on cognitive function. Consequently, glycopyrrolate can become a valid option for treating CIS. Observations from our study serve as a springboard for additional large-scale prospective trials. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Comparison of the efficacy and impact on cognition of glycopyrrolate and biperiden for clozapine-induced sialorrhea in schizophrenic patients: a randomized, double-blind, crossover study. [2010]
CIS... CONCLUSION: We provide evidence, for the first time, of the efficacy of

Modulation of memory and visuospatial processes by biperiden and rivastigmine in elderly healthy subjects. [2005.09]
RATIONALE: The central cholinergic system is implicated in cognitive functioning. The dysfunction of this system is expressed in many diseases like Alzheimer's disease, dementia of Lewy body, Parkinson's disease and vascular dementia. In recent animal studies, it was found that selective cholinergic modulation affects visuospatial processes even more than memory function. OBJECTIVE: In the current study, we tried to replicate those findings. In order to investigate the acute effects of cholinergic drugs on memory and visuospatial functions, a selective anticholinergic drug, biperiden, was compared to a selective acetylcholinesterase-inhibiting drug, rivastigmine, in healthy elderly subjects... CONCLUSIONS: These results implicate acetylcholine as a modulator not only of memory but also of visuospatial abilities.

[The use of biperiden (akineton) in patients with ephedrone encephalopathy]. [Article in Russian] [2013]
An open comparative cross-over trial of the selective central M1 cholinoreceptors blocker - biperiden (akineton) was carried out in 35 patients with efedron encephalopathy (EEP) with mean illness duration 6,9 years... Among patients switched to biperiden, 36% preferred to continue with the drug and only 12% preferred trihexyphenidyl.

A comparison of scopolamine and biperiden as a rodent model for cholinergic cognitive impairment. [2011.06]
CONCLUSION: Muscarinic m1 antagonists should be considered an interesting alternative for SCOP as a pharmacological model for cholinergic mnemonic deficits in animals.

more studies >>

Clinical Trials Related to Akineton (Biperiden)

Cocaine/Crack and Reduction of Compulsion With Biperiden [Recruiting]
Cocaine consumption affects around 13. 4 mi people or 0. 3% of the world population between 15 and 64 years old. The drug dependence has been described by many authors as a dysfunction of the brain reward system. Considering the effects of the cholinergic system on the drug reward and self-administration mechanisms, acetylcholine (Ach) may play an important role on cocaine dependence process. Then the present study aims to evaluate biperiden efficacy (a cholinergic antagonist) in attenuate compulsion, one o the main symptoms of the drug dependence. To accomplish this purpose 60 cocaine or crack male users between 18 and 50 years old will be study. This is a double-blind controlled and randomized placebo study. All the patients will be treated with brief intervention therapy (BIT), and half of them will receive biperiden (6mg/day) while the other half will receive placebo. The treatment efficacy will be evaluated through the comparison between the values obtained on the following measures before and after the treatment: Craving scale of Minnesota and Cocaine/crack consumption questionnaire, and the presence of the cocaine metabolite (benzoylecgonine) on urine.

Efficacy of Caffeine, With and Without Biperiden, in the Detoxification of Cocaine Dependent Patients [Recruiting]
The aim of this study is to assess the efficacy of caffeine compared to placebo in detoxifying cocaine dependent patients. Caffeine potentiation with biperiden will be also studied.

108 with cocaine dependence will be randomized to receive caffeine (300 - 1200 mg t. i.d.)

plus biperidene (8 mg b. i.d.) or caffeine (300 - 1200 mg t. i.d.) with placebo or placebo

during 6 months.

Primary efficacy outcomes will be 1) patient comfort assessed with abstinence symptomatology, craving for cocaine and mental status during detoxifying period, 2) study retention and 3) cocaine use.

Brain dopamine system will be assessed thru IBZM-SPECT and the apomorphine test.

Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence [Recruiting]
The aim of this study is to assess the efficacy of caffeine compared to placebo as a maintenance treatment for cocaine dependence. Caffeine potentiation with biperiden will be also studied. Ninety patients with snorted/sniffed cocaine dependence will be randomized to receive

caffeine (300 - 1200 mg t. i.d.) plus biperidene (8 mg b. i.d.) caffeine (300 - 1200 mg

t. i.d.) with placebo or placebo during 10 days in an in-hospital setting.

Use of Biperiden for the Prevention of Post-traumatic Epilepsy [Recruiting]
There is no AED or medication that has been demonstrated to affect the development of post-traumatic epilepsy. Biperiden is a cholinergic antagonist, acting in the muscarinic receptor, that is widely used as an anti Parkinson drug. The investigators data with animal models of epilepsy indicate that anti-muscarinic agents might affect the natural course of the disease in the case of post-traumatic epilepsy.

Optimization of Procedural Sedation Protocol Used for Dental Care Delivery in People With Mental Disability [Recruiting]
The study aims to compare procedural sedation protocols, specifically applied for the delivery of regular dental care in persons with a mental disability. The primary objectives are:

- To assess the level of cooperation during regular dental care using different

procedural sedation protocols

- To assess patient safety during regular dental care using different sedation protocols

- To assess patient comfort and possible side-effects after regular dental care using

different sedation protocols

more trials >>

Reports of Suspected Akineton (Biperiden) Side Effects

Renal Failure Acute (16)Acute Hepatic Failure (16)Thrombocytopenia (14)Self Injurious Behaviour (14)Multiple Drug Overdose Intentional (12)Tachycardia (10)Ileus (9)Neuroleptic Malignant Syndrome (8)Delirium (7)Rhabdomyolysis (6)more >>


Page last updated: 2014-11-30

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014